Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. (Q45734380)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11755504%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

title

Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11755504%20AND%20SRC:MED&resulttype=core&format=json

cost-effectiveness analysis

5 December 2019

main subject

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11755504%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

author name string

Z M Younossi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11755504%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

language of work or name

English

0 references

publication date

1 December 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11755504%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Medicine

5 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11755504%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

volume

111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11755504%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11755504%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

page(s)

614-621

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11755504%20AND%20SRC:MED&resulttype=core&format=json

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

5 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Hepatitis C: an update on the silent epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

The long-term pathological evolution of chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Changes in liver histopathology in women infected with hepatitis C through contaminated anti-D immunoglobulin injections in Ireland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Risk Factors for Hepatocellular Carcinoma among Patients with Chronic Liver Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

An analysis of liver transplant experience from 37 transplant centers as reported to Medicare.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Compensated cirrhosis: Natural history and prognostic factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Comparison of two anti‐hepatitis C virus enzyme‐linked immunosorbent assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Increased detection of hepatitis C virus infection in commercial plasma donors by a third-generation screening assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Increased detection of antibody to hepatitis C virus in renal transplant patients by third-generation assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Sensitivity and specificity of three third-generation anti-hepatitis C virus ELISAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Performance of three generations of anti-hepatitis C virus enzyme-linked immunosorbent assays in donors and patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Assessment of utilities and health-related quality of life in patients with chronic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

The impact of diagnosis of hepatitis C virus on quality of life.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Cost and health implications of cholesterol lowering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Hepatitis C, interferon alfa, and depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Hepatitis C in asymptomatic blood donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Long-term course of interferon-treated chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Impact of liver transplantation on health-related quality of life.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

45-year follow-up of hepatitis C virus infection in healthy young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

Evaluation of a membrane filter assay system, Ortho HCV Ab Quick Pack, for detection of anti-hepatitis C virus antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900951-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(01)00951-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11755504%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

1 reference